Chanhassen, Minnesota, U.S., October 8, 2026
Alpheus Medical has announced the initiation of a new clinical trial evaluating its investigational Porphyrin Metabolite Activation (PoMA™) therapy in patients with newly diagnosed butterfly glioblastoma, an aggressive form of brain cancer that affects both cerebral hemispheres. The study, known as the Alpheus Butterfly trial (NCT07862647), is designed to evaluate the safety and clinical activity of a drug-led treatment approach that combines an oral drug with non-invasive, low-intensity ultrasound. The trial is intended to address a patient population that has historically faced limited treatment options and has often been excluded from clinical studies because of the tumor’s bilateral spread. PoMA therapy will be investigated alongside standard-of-care treatment, with enrollment required before patients begin chemoradiation. The study represents a new step in Alpheus Medical’s clinical development strategy for glioblastoma, although the investigational therapy has not been approved by the U.S. Food and Drug Administration (FDA).
Alpheus Medical Targets Aggressive Butterfly Glioblastoma
Butterfly glioblastoma is a particularly challenging form of glioblastoma in which the tumor extends across the corpus callosum, the structure connecting the brain’s two hemispheres. This pattern of spread can make surgical removal difficult or impossible and complicates treatment planning. According to the company’s announcement, published research has reported a median survival of approximately three to six months for this form of the disease. Patients with bilateral or multifocal tumors may also face barriers to clinical trial participation because some studies exclude these disease characteristics. The Alpheus Butterfly trial has been designed specifically for patients with newly diagnosed butterfly glioblastoma, with the aim of evaluating a treatment approach intended to reach tumor regions across both hemispheres. The study will assess the safety and clinical activity of PoMA therapy when used alongside standard treatment. The trial is not intended to replace established care, and participating patients will continue to receive treatment according to the study protocol and their clinical team’s guidance. Because the treatment is investigational, its potential benefits and risks must be evaluated through clinical research before any conclusions can be drawn about its effectiveness.
PoMA Therapy Combines 5-ALA and Ultrasound
Alpheus Medical’s PoMA therapy combines oral 5-aminolevulinic acid (5-ALA) with proprietary low-intensity defocused ultrasound. After administration, 5-ALA leads to the accumulation of protoporphyrin IX (PpIX) in tumor cells. The ultrasound is then used to activate the tumor-localized metabolite, with the goal of generating localized pharmacological activity in affected tissue. The approach is designed to support treatment across both cerebral hemispheres without requiring an invasive procedure. The company states that therapy is delivered while the patient is awake in an outpatient setting and is designed to be repeatable. This drug-centered strategy differs from approaches that rely solely on localized treatment of a visible tumor, as butterfly glioblastoma can extend across a broad region of the brain. The clinical trial will investigate whether this approach can be administered safely and whether it demonstrates clinical activity in the targeted patient population. PoMA remains investigational, and its safety and efficacy have not been established. The trial’s findings will be needed to determine whether the proposed treatment mechanism translates into meaningful outcomes for patients.
Advertisement
Clinical Trial Opens Enrollment in the United States
The multicenter Alpheus Butterfly study is enrolling patients with newly diagnosed butterfly glioblastoma. The Dent Neurologic Institute in Buffalo, New York, is currently recruiting participants, with additional U.S. clinical centers expected to come online in the coming months, according to the announcement. A key consideration is the timing of enrollment: patients must join the study before beginning standard chemoradiation treatment. This requirement makes early communication between patients, caregivers and treating clinicians important for those who may be interested in learning about eligibility. The protocol defines who can participate and how the investigational therapy will be integrated with standard care. Alpheus Medical also reported raising additional financing to support the Butterfly GBM study and the continued development of PoMA therapy. The company is separately evaluating its lead program in a randomized Phase 2b trial for newly diagnosed glioblastoma, extending its broader research into drug-led ultrasound activation for brain cancer. The launch of the Butterfly trial highlights ongoing efforts to develop new treatment strategies for patients with difficult-to-treat brain tumors. The study is an early clinical evaluation, not evidence of established treatment benefit or regulatory approval. Its results will help determine the safety, feasibility and potential role of PoMA therapy in this underserved patient population.
Source: Alpheus Medical press release
